Article
Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.
Journal of translational medicine - 20 Jun 2015
Yousef Sara, Heise Johanna, Lajmi Nesrine, Bartels Katrin, Kröger Nicolaus, Luetkens Tim, Atanackovic Djordje
Abstract excerpt
BACKGROUND: Most patients with multiple myeloma (MM) will relapse after an initial response and eventually succumb to their disease. This is due to the persistence of chemotherapy-resistant tumor cells in the patients' bone marrow (BM) and immunotherapeutic approaches could contribute to eradicating these remaining cells. We evaluated SLLP1 as a potential immunotherapeutic target for MM. METHODS: We determined...
Topics
- Adult
- Aged
- Aged, 80 and over
- Amino Acid Sequence
- Antibody Formation
- Bone Marrow
- Cell Line, Tumor
- Epitopes
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunoglobulin G
- Immunotherapy
- Isoantigens